老年STEMI患者完全血运重建与仅罪犯血管血运重建:个体患者荟萃分析
该个体患者数据荟萃分析纳入7项随机临床试验共1733例≥75岁STEMI合并多支病变患者,比较完全血运重建与仅罪犯血管血运重建。中位随访2.5年,完全血运重建在4年内降低主要终点(死亡、心梗或缺血驱动血运重建),但在最长随访时未显著降低主要终点,而心血管死亡或心梗复合终点在最长随访时显著降低。
要点
- ≥75岁STEMI多支病变患者,完全血运重建在4年内降低主要复合终点。
- 最长随访时主要终点未显著降低,但心血管死亡或心梗复合终点显著降低。
- 长期死亡率在完全血运重建与仅罪犯血管血运重建间无差异。
核心结论
- 在≥75岁STEMI合并多支病变患者中,完全血运重建在4年内降低死亡、心梗或缺血驱动血运重建的主要终点。
- 在最长随访时,完全血运重建降低心血管死亡或心梗复合终点,但未显著降低主要终点。
- 长期死亡率在两种策略间无差异。
研究设计与样本
- 个体患者数据荟萃分析,系统检索PubMed、Embase和Cochrane数据库筛选比较完全与仅罪犯血管血运重建的随机临床试验。
- 纳入7项随机临床试验共1733例患者,其中仅罪犯血管血运重建917例,完全血运重建816例。
- 患者年龄≥75岁,中位年龄79岁(四分位距77-83),女性595例(34%)。
- 随访最短6个月,最长6.2年,中位2.5年(四分位距1-3.8)。
主要发现
- 完全血运重建在4年内降低主要终点(风险比0.78,95%CI 0.63-0.96)。
- 最长随访时完全血运重建未显著降低主要终点(风险比0.83,95%CI 0.69-1.01)。
- 最长随访时完全血运重建显著降低心血管死亡或心梗复合终点(风险比0.76,95%CI 0.58-0.99)。
- 每年截尾随访时均观察到心血管死亡或心梗复合终点的降低。
- 长期死亡率在完全血运重建与仅罪犯血管血运重建组间无差异。
临床怎么用
- 对于≥75岁STEMI合并多支病变患者,可考虑完全血运重建以降低4年内主要复合终点。
- 完全血运重建对心血管死亡或心梗的获益在长期随访中持续存在,但需权衡主要终点未显著降低及死亡率无差异。
局限性
- 随访时间异质性较大(最短6个月至最长6.2年)。
- 原文未报告各试验的具体偏倚风险或异质性分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Complete revascularization is the standard treatment for patients with ST-segment-elevation myocardial infarction and multivessel disease. The FIRE trial (Functional Assessment in Elderly Myocardial Infarction Patients With Multivessel Disease) confirmed the benefit of complete revascularization in a population of older patients, but the follow-up is limited to 1 year. Therefore, the long-term benefit (>1 year) of this strategy in older patients is debated. To address this, an individual patient data meta-analysis was conducted in patients with ST-segment-elevation myocardial infarction ≥75 years of age enrolled in randomized clinical trials investigating complete versus culprit-only revascularization strategies. METHODS: PubMed, Embase, and the Cochrane database were systematically searched to identify randomized clinical trials comparing complete versus culprit-only revascularization. Individual patient-level data were collected from the relevant trials. The primary end point was death, myocardial infarction, or ischemia-driven revascularization. The secondary end point was cardiovascular death or myocardial infarction. RESULTS: Data from 7 randomized clinical trials encompassing 1733 patients (917 randomized to culprit-only and 816 to complete revascularization) were analyzed. The median age was 79 [interquartile range, 77-83] years. Of the patients, 595 (34%) were female. Follow-up ranged from a minimum of 6 months to a maximum of 6.2 years (median, 2.5 [interquartile range, 1-3.8] years). Complete revascularization reduced the primary end point up to 4 years (hazard ratio, 0.78 [95% CI, 0.63-0.96]) but not at the longest available follow-up (hazard ratio, 0.83 [95% CI, 0.69-1.01]). Complete revascularization significantly reduced the occurrence of cardiovascular death or myocardial infarction at the longest available follow-up (hazard ratio, 0.76 [95% CI, 0.58-0.99]). This was observed even when censoring the follow-up at each year. Long-term rate of death did not differ between complete and culprit-only revascularization arms. CONCLUSIONS: In this individual patient data meta-analysis of older patients with ST-segment-elevation myocardial infarction and multivessel disease, complete revascularization reduced the primary end point of death, myocardial infarction, or ischemia-driven revascularization up to 4 years. At the longest follow-up, complete revascularization reduced the composite of cardiovascular death or myocardial infarction but not the primary end point. REGISTRATION: URL: https://www.crd.york.ac.uk/prospero/; Unique identifier: CRD42022367898.
引用
- Campo G, Böhm F, Engstrøm T, et al. Complete Versus Culprit-Only Revascularization in Older Patients With ST-Segment-Elevation Myocardial Infarction: An Individual Patient Meta-Analysis. Circulation. 2024. PMID: 39217603. doi:10.1161/CIRCULATIONAHA.124.071493
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。